NASDAQ: YMABY Mabs Therapeutics Inc Stock
$4.20-0.03 (-0.71%)
Updated Apr 29, 2025
YMAB Price
$4.20
Fair Value Price
N/A
Market Cap
$189.92M
52 Week Low
$3.84
52 Week High
$17.78
P/E
-6.27x
P/B
2.06x
P/S
3.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$87.69M
Earnings
-$29.67M
Gross Margin
82.6%
Operating Margin
-35.58%
Profit Margin
-33.8%
Debt to Equity
0.3
Operating Cash Flow
-$16M
Beta
1.48
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
YMAB Overview
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine YMAB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
YMAB
Ranked#158 of 462
Ranked#158 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important YMAB news, forecast changes, insider trades & much more!
YMAB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how YMAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
YMAB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
YMAB is good value based on its book value relative to its share price (2.06x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
YMAB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more YMAB due diligence checks available for Premium users.
Valuation
YMAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.27x
Industry
-158.75x
Market
29.19x
YMAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.06x
Industry
4.37x
YMAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
YMAB's financial health
Profit margin
Revenue
$26.5M
Net Income
-$6.8M
Profit Margin
-25.6%
YMAB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
YMAB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$119.9M
Liabilities
$27.9M
Debt to equity
0.3
YMAB's short-term assets ($98.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YMAB's short-term assets ($98.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YMAB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
YMAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$0.0
Financing
$986.0k
YMAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
YMAB vs Biotech Stocks
Y Mabs Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.